Hexokinase2-engineered T cells display increased anti-tumor function.

Area of Science:

• Immunology
• Cancer Biology
• Metabolic Engineering

Background:

• T cells struggle metabolically in the tumor microenvironment (TME) due to nutrient competition from cancer cells.
• This competition impairs T cell anti-tumor activity by reducing critical metabolic functions like glycolysis.
• Hexokinase 2 (HK2) is essential for T cell glycolysis and overall functionality.

Purpose of the Study:

• To enhance T cell anti-tumor immunity by genetically engineering T cells to overexpress Hexokinase 2 (HK2).
• To evaluate the metabolic and therapeutic efficacy of HK2-engineered T cells in vitro and in vivo.

Main Methods:

• Primary human T cells were genetically modified to overexpress HK2 and a tumor-specific receptor.
• Engineered T cells underwent in vitro testing for metabolic function and activation.
• In vivo efficacy was assessed using a human tumor xenograft model.

Main Results:

• HK2-engineered T cells demonstrated significantly increased glycolytic capacity.
• Enhanced metabolic activity correlated with improved cytokine secretion and activation marker expression.
• In vivo studies showed delayed tumor growth and improved survival in the xenograft model.

Conclusions:

• Overexpression of HK2 enhances T cell metabolic fitness and functionality within the TME.
• This metabolic enhancement translates to improved anti-tumor therapeutic efficacy.
• HK2 engineering represents a promising strategy for next-generation immunotherapies targeting T cell metabolism.